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drugs by assessing their sequential use in the case of failure of either of them. This retrospec tive survey included 71 patients with ulcerative colitis and, perhaps question ably, a further subset of 15 patients with a diagnosis of indeterminate colitis. These 86 patients were admitted to several European centers between 2000 and 2008 to be treated for steroid-refractory IBD: 65 received ciclosporin first and were then switched to infliximab, 21 received infliximab followed by ciclosporin. The median follow-up was 22.6 months. The authors found that the percentage failure of the second-line (rescue) therapy was not signifi cantly different for the two sequences (53% for ciclosporin followed by infliximab and 66% for infliximab followed by ciclosporin). Overall, 40% of the patients were colectomy-free at 1 year, 19 of the 86 (22%) experienced considerable adverse events, including serious infections in nine patients, and there was one fatality.
Comparison of these findings (Table 1 ) with those of Maser et al., who performed a study with a similar design, 10 allows the following considerations to be made. The authors should be commended for daring to re-assess the potential of this rescue therapy in a much larger number of patients than previously assessed, thus seeking to extend the limits of the acceptable risks in the treatment of difficult ulcerative colitis. However, the replication of the same study design (a retrospective survey of patients for whom the choice of the first drug was at the discretion of individual physicians) means that the study by Leblanc et al. is unlikely to progress the findings of the previous paper. Indeed, Leblanc and coworkers seem to have achieved similar, or even worse, results than those of the previous study (Table 1) . Notably, the incidence of serious infections was high in both reports-this finding raises an important safety issue, and does not modify the discouraging recommendations of both the European and American Crohn's Colitis Foundations that such strategies should no longer be attempted.
In making a conclusive comment on these data, the tremendous impact that genome-wide association studies are having on our specialty can no longer be ignored. To date, 99 susceptibility loci for IBD have been characterized, and this knowledge is changing our understanding of the disease as well as our therapeutic choices. Mucosal gene studies have already begun to identify gene signatures that predict response or resistance to anti-TNF drugs, 11 thus making the design of Leblanc and colleagues' study somewhat obsolete. More generally, genome-wide association studies indicate that ulcerative colitis might be a mucosal permeability disease, whereas Crohn's disease could be an immune deficiency disorder. This finding will perhaps pave the way to the progressive reduction in the use of the current immune interventions.
HEPATITIS

PEG-IFN for the treatment of hepatitis D
Alessia Ciancio and Mario Rizzetto
Currently, there is no satisfactory treatment for patients coinfected with hepatitis B virus and hepatitis D virus, which causes hepatitis D-the most severe form of hepatitis. A recent study has assessed the safety and efficacy of PEG-IFN-α2a and adefovir alone and in combination in these patients. Hepatitis D is caused by the hepatitis D virus (HDV), a defective subviral pathogen that requires concomitant infection with the hepatitis B virus (HBV) to be infective. Although the double viral infection would seem to be more vulnerable to antiviral attacks than a single viral infection (as patients with the double infection have two distinct viral targets), chronic hepatitis D remains the most difficult to treat of the viral hepatitides. The minimalist HDV has no replicative machinery of its own; it is replicated by mammalian RNA polymerases and, therefore, does not encode specific enzymatic functions that can be targeted by antiviral agents. 1 Ongoing HDV infections inhibit the synthesis of the concomitant HBV, to the point that HBV DNA in the serum is often undetectable or barely detectable. Not surprisingly, attempts to use lamivudine to further inhibit and possibly eradicate the HBV, thus depriving the HDV of its biological substrate, have not been successful.
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The current treatment for patients with chronic hepatitis D remains empirical and still relies on interferon (IFN), which was first used in the 1980s and is the only drug licensed for the treatment of patients with this disease. 3 In the 1990s, several studies showed that conventional IFN-α provides some therapeutic efficacy in patients with chronic hepatitis D, with about 20% of the patients maintaining a biochemical and virological response 6 months after a 6-12 month course of therapy; however, these studies included small numbers of patients, the clinical features of the patients were heterogeneous and treatment protocols varied in the different series. 3 In the 2000s, the advent of PEG-IFNs and their increased efficacy compared with conventional IFNs further stimulated thera peutic interest in this group of drugs for the treatment of chronic hepatitis D. The initial experience with this therapy was obtained from the use of PEG-IFN-α2b. Treatment with this type of IFN induced rates of sustained virological responses that varied from 17% to 43%. [4] [5] [6] However, these studies also included only a small number of patients and are difficult to compare because of the clinical heterogeneity of the patients; the highest rates of sustained virological response were reported in a series of 14 patients, most of whom did not have cirrhosis (a common complication in patients with HDV). 5 The paper by Wedemeyer and coworkers 7 provides information on what can be achieved with PEG-IFN-α2a in patients infected with HBV and HDV. Wedemeyer et al. compared the efficacy of PEG-IFN-α2a alone versus its combination with adefovir and adefovir monotherapy. They recruited 90 patients; 31 were assigned to a 48-week therapy with 180 μg per week of PEG-IFN-α2a, plus 10 mg per day of adefovir; 29 received PEG-IFN-α2a only; 30 received adefovir only. This study is the largest on HDV therapy conducted to date.
The primary outcome of the study (normal levels of alanine aminotransferase and undetectable levels of HDV RNA at the end of therapy) was only obtained in 7% of the patients in each PEG-IFN-α2a group. However, during therapy HDV RNA became undetectable in the serum of seven patients in each of the groups that received PEG-IFN-α2a (23-24%) versus none in the adefovir monotherapy group; three patients lost the viral marker during followup after completion of the therapy, bringing the overall figure for viral clearance to 28% in the treatment arms that used PEG-IFN-α2a.
The data from this well-designed and well-conducted trial in a reasonably large number of patients who have HDV indicate that HDV can be controlled with PEG-IFN-α2a in almost 30% of patients. However, adefovir, which is active against HBV, was not efficacious either alone or in combination with PEG-IFN-α2a.
In all patients, the adverse events were acceptable and not different from those expected with PEG-IFN monotherapy. Liver disease in one patient with a low platelet count, and presumably advanced cirrhosis, decompensated during therapy, which emphasizes the need to carefully select patients with HDV for PEG-IFN therapy, as many of these patients have cirrhosis by the time of clinical presentation.
In this study, as in previous studies, 4 ,6 the pattern of HDV RNA expression during therapy was somewhat inconsistent. Relapses occurred in patients who had cleared HDV RNA while on therapy and viral clearance was observed during the follow-up in patients who had detectable levels of HDV RNA at the end of therapy. The predict ability of a patient's response, therefore, seems to be an issue with this therapy and a period of treatment longer than 48 weeks could be considered as standard protocol.
Although the results of this study indicate that PEG-IFN-α2a can induce remission of viremia in a considerable proportion of patients with chronic hepatitis D, the ultimate clinical meaning of this therapeutic success remains unclear. No notable histological amelioration was found in paired biopsy samples, in fact fibrosis and histological activity scores worsened in a proportion of patients given PEG-IFN-α2a, and the levels of alanine aminotransferase also normalized in patients who had detectable levels of HDV RNA throughout the follow-up.
In the context of HBV infection, HDV remains infectious and ready to reactivate even when the virus is at very low levels. 8 The infectious potential of HDV will probably remain high even in patients who have numbers of viral copies in their serum well below the 120 copies per ml that represented the lower limit of HDV RNA detection of the analytical test used in the study by Wedemeyer and colleagues. Thus, it is uncertain whether not detecting HDV RNA 6 months after therapy in the presence of hepatitis B surface antigen (HBsAg) does in fact indicate a change in the natural history of chronic hepatitis D or represents an ephemeral event with no long-term clinical effects. Only anecdotal reports exist of long-term clinical ameliorations after treatment with IFN 9 and longitudinal retrospective surveys of previously treated patients are needed to establish the true clinical value of the current IFN therapy in patients with chronic hepatitis D.
The relevance of HBsAg to the therap eut ic outcome was address e d by Wedemeyer and colleagues. They determined the decline of HBsAg induced in the three treatment arms and found that only the combination of PEG-IFN-α2a with adefovir resulted in a considerable decline in the levels of the antigen in serum; the HBsAg level diminished by at least 1 log 10 IU/ml in approximately onethird of patients who received combination therapy. This finding points to a more incisive approach to therapy for patients with hepatitis D. This approach would involve the combination of drugs, such as PEG-IFN with adefovir, which are able not only to diminish HDV RNA synthesis but also to interfere with the synthesis of the HBsAg or to change its structure; modifications of the HBsAg could block hepatitis D virion assembly and prevent HDV reinfection in new hepatocytes.
1 Current efforts to manipulate HBsAg such that it can no longer attach to HDV receptors promise to have clinical applications in the near future. 
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Dried plums (prunes) for the treatment of constipation
S. Mark Scott and Charles H. Knowles
Constipation is a very common condition that is frequently managed suboptimally. A recent single-blind, randomized, crossover study has reported the superior effects of dried plums (prunes) over the stoolbulking fiber supplement psyllium in the treatment of mild to moderate symptoms of constipation. Throughout history, the healing properties of food have been espoused by cultures worldwide. Indeed, 2,500 years ago, it was Hippocrates who promoted the value of letting "food be thy medicine and medicine be thy food", though it has taken an increasingly health-conscious populace to help revitalize this philosophy over the past couple of decades. Quite logically, there is no area where the relationship between food and health is more keenly observed than with regard to disorders of gastrointestinal function. Many patients with chronic constipa tion, which afflicts around 15% of community-dwelling adults, 1 are convinced of the importance of food in both causing and relieving their symptoms. 2 Recommended first-line therapy is a gradual increase in fiber intake, either incorporated into the diet, or through standardized fiber supplements. 3 A crosssectional survey of 518 patients with a primary diagnosis of constipa tion attending a tertiary-referral center revealed that ~85% regularly increased their dietary fiber intake, of whom >30% did this on a daily basis. 4 However, many doctors' knowledge of nutrition is suboptimal when faced with providing constipation management advice, and thus there is an over-reliance on the prescription of pharmaceutical fiber supplements (for example, psyllium), as well as other laxatives, rather than 'natural' alternatives.
Furthermore, in most health-care systems, there is a natural separation of interventions into clusters of care depending on the patient's place in a notional algorithm of treatment, which progresses from self-therapy, through primary (community) and secondary (hospital) care, to tertiary treatments, including surgery for refractory cases. 5 However, there are currently no nationally or internationally agreed algorithms for such therapy progression with regard to constipation, and consequently there are considerable variations in clinical practice. A significant gap in the evidencebase required to create such an algorithm is the difficulty in equating modern evidence from definitive clinical trials with that of received wisdom as to the efficacy of older laxatives. Thus, although meta-analyses and reviews over the past few years have highlighted some proven agents, 6 there are a number of older agents, including foodstuffs, whose efficacy has never been demonstrated to the standards of modern clinical trial design, but whose potential role it would be ill-advised to ignore.
